The purpose is to study the population pharmacokinetics, effectiveness and safety of antineoplastic drugs (Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib, Imatinib, Lapatinib, etc) in elderly patients and recommend optimized dosage regimens.
Study Type
OBSERVATIONAL
Enrollment
500
As part of routine treatment.
Shandong Provincial Qianfoshan Hospital
Jinan, Shandong, China
RECRUITINGThe peak plasma drug concentration of antineoplastic drugs.
To detect the peak plasma drug concentration of antineoplastic drugs.
Time frame: at (0-4) hours after administration
The random plasma drug concentration of antineoplastic drugs.
To detect the random plasma drug concentration of antineoplastic drugs.
Time frame: at (4-10) hours after administration
The trough plasma drug concentration of antineoplastic drugs.
To detect the trough plasma drug concentration of antineoplastic drugs.
Time frame: at (1-2) hours before the next administration
Objective ResponseRate ,ORR
Time frame: Enrollment to end of treatment up to 5 years
Overall Survival ,OS
Time frame: First day of study treatment to the date of death due to any cause, assessed up to 5 years
Progression-free Survival ,PFS
Time frame: First day of study treatment to the date of disease progression or death due to any cause, assessed up to 5 years
Time to Progression ,TTP
Time frame: Enrollment to end of treatment up to 5 years
The incidence of adverse drug reaction
Time frame: Enrollment to end of treatment up to 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.